In the literature, BTKi (22, 23), lenalidomide (24, 25), PD-1 inhibitor (26), BCL-2i (27), idelalisib (28) and interferon α (29) had been reported to synergize with CAR-T cells in the treatment of various hematologic malignancies, and these compounds may be potential therapy choices for combination therapies with CAR-T therapy. Here, IBTK is linked to hematologic disorder.